Bifogade filer
IRLAB to present data from the Phase IIb study of mesdopetam in PD-LIDs at the MDS Congress 2023
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Gothenburg, Sweden, June 20, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will present an abstract at the International Congress of Parkinson’s Disease and Movement Disorders®, MDS Congress, in Copenhagen, Denmark from August 27-31, 2023. The abstract “Results from IRL790C005 - A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson’s Disease” will be presented by Joakim Tedroff, Chief Medical Officer at IRLAB.
The abstract titled “Results from IRL790C005 - A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson’s Disease”, was authored by Angelo Antonini at the Department of Neuroscience, Padua University; Susanna Waters, Clas Sonesson, Johanna Landström, Nicholas Waters and Joakim Tedroff at Integrative Research Laboratories Sweden AB (IRLAB).
The International Parkinson and Movement Disorder Society (MDS) gathers thousands of the field's clinicians, researchers, trainees and industry supporters with an interest in the current research and approaches for the diagnosis and treatment of movement disorders on an annual basis at its International Congress of Parkinson's Disease and Movement Disorders®. The purpose of the MDS International Congress is to share ideas, encourage interest among all those involved in the care and research of movement disorders, to participate in the activities of MDS, and to advance the related clinical and scientific discipline.
Details of the poster presentation:
Abstract Title: Results from IRL790C005 - A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson’s Disease
Abstract Number: 22
Abstract Category: Parkinson’s Disease: Clinical Trials
Presentation Date: Monday, August 28
Presentation Time: 13:00 - 15:00
Poster Hall: Exhibition Hall
All accepted abstracts will be published in an online supplement to Movement Disorders, the official journal of the International Parkinson and Movement Disorders Society, and in the searchable MDS abstract website, mdsabstracts.org on August 27, 2023, 08:00 CEST.